• Yeo-Pyo Yun
  • Hwan-Soo Yoo
  • Yoon-Seok Roh
Yeo-Pyo Yun
043-261-2821
ypyun@chungbuk.ac.kr

Education & Career

  • 1976-1980 B.Pharm in Manufacturing Pharmacy, Seoul National University
  • 1980-1982 M.Pharm in Pharmacy, Seoul National University
  • 1982-1986 Dr.Pharm in Pharmacy, Seoul National University
  • 2018. 7. Honorary Doctorate, Hokkaido University, Japan
  • 1986-Present Professor, Chungbuk National University
  • 1988-1990 Visiting Fellow, National Institutes of Health (USA)
  • 2000-2002 Dean, College of Pharmacy
  • 2001-2002 Vice President, Pharmaceutical Society of Korea
  • 2004-2006 Director, Research Institute of Development of Pharmaceutical Resources
  • 2007-2008 Vice President, Korean Society of Food Hygiene and Safety
  • 2008-2010 Governer, Korea Food and Drug Adminstration
  • 2011-2014 Chief Director, Osong Medical Innovation Foundation
  • 2015-2016 Chairman, Korea Association of Flagship National University Presidents
  • 2017 Chairman, Korea Association of National and Public University Presidents
  • 2014-2018 President, Chungbuk National University


Research Areas

  1. Development of Drug for Cardiovascular Disease (심혈관질환 약물 개발)
  2. Pharmacological Screening & its Mechanism of Agents for Thrombosis/ Platelet Aggregation
    (혈전질환 예방.치료제 약리활성평가 및 작용기전)
  3. Pharmacological Screening & its Mechanism of Agents for Atherosclerosis/ Restenosis
    (동맥경화/혈관재협착 예방.치료제 약리활성평가 및 작용기전)


 

Selected Publications

  1. Antiplatelet action of indirubin-3'-monoxime through suppression of glycoprotein VI-mediated signal transduction: a possible role for ERK signaling in platelets. Vascul Pharmacol. 2014 Dec;63(3):182-92.
  2. Piperine inhibits the activities of platelet cytosolic phospholipase A2 and thromboxane A2 synthase without affecting cyclooxygenase-1 activity: different mechanisms of action are involved in the inhibition of platelet aggregation and macrophage inflammatory response. Nutrients. 2014 Aug 22;6(8):3336-52.
  3. Sulforaphane attenuates obesity by inhibiting adipogenesis and activating the AMPK pathway in obese mice. J Nutr Biochem. 2014 Feb;25(2):201-7.
  4. Hinokitiol inhibits cell growth through induction of S-phase arrest and apoptosis in human colon cancer cells and suppresses tumor growth in a mouse xenograft experiment. Nat Prod. 2013 Dec 27;76(12):2195-202.
  5. Echinacea purpurea root extract enhances the adipocyte differentiation of 3T3-L1 cells. Arch Pharm Res. 2014 Jun;37(6):803-12.
  6. Sulforaphane inhibits PDGF-induced proliferation of rat aortic vascular smooth muscle cell by up-regulation of p53 leading to G1/S cell cycle arrest. Vascul Pharmacol. 2013 Jul-Aug;59(1-2):44-51.
  7. Camptothecin inhibits platelet-derived growth factor-BB-induced proliferation of rat aortic vascular smooth muscle cells through inhibition of PI3K/Akt signaling pathway. Exp Cell Res. 2013 Apr 15; 319(7):982-91.
  8. Green tomato extract attenuates high-fat-diet-induced obesity through activation of the AMPK pathway in C57BL/6 mice. J Nutr Biochem. 2013 Jan;24(1):335-42.
  9. Epigallocatechin-3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its anti-neuroinflammatory properties. J Nutr Biochem. 2013 Jan;24(1): 298-310.
  10. Quantitative analysis of sphingomyelin by high-performance liquid chromatography after enzymatic hydrolysis. Evid based Complement Alternat Med. 2012;2012:396218.


Patents

  1. Pharmaceutical composition for obovatol for the prevention and treatment restenosis
  2. Novel glycolipid derivative compounds and their therapeutic use for vascular smooth muscle cell hyper-proliferation


Awards

  1. 2002 Excellent Science and Technology Paper Award
  2. 2012 Order of Service Merit - Yellow Stripes
  3. 2017 The Korea’s Influential CEO in 2017
Hwan-Soo Yoo
043-261-3215
yoohs@chungbuk.ac.kr

Education & Career

  • 1979-1983: BS, College of Pharmacy, Chungbuk National University
  • 1983-1985: MS, College of Pharmacy, Seoul National University
  • 1988-1994: Ph.D, College of Pharmacy, University of Georgia (USA)
  • 1994-1996: Post Doc., National Institute of Health (USA)
  • 2000-2002: Visiting Researcher, College of Medicine, Emory University (USA)
  • 1996-present: Professor, College of Pharmacy, Chungbuk National University


Research Areas

  1. Sphingolipids?
    Ceramide synthesis occurs in the endoplasmic reticulum, and is initiated by serine palmitoyltransferase, a pyridoxal 5-phosphate dependent enzyme, to produce 3-ketosphinganine which results from the condensation of serine and palmitoyl-CoA. Ceramide can be metabolized to glycosphingolipids by a glucosylceramide synthase. Sphingolipid turnover involves removal of the sugars by exoglycosidases and the phosphorylcholine of sphingomyelin by sphingomyelinase. After removal of the sphingolipid head group, Ceramide can be either reutilized for complex sphingolipid formation or undergo further breakdown processes. Ceramide at the C-1 position was phosphorylated by ceramide kinase to ceramide 1-phosphate.

  2. Adipocyte Differentiation
    Adipocytes are a major site for energy storage (in the form of triglycerides) for use during periods of caloric insufficiency. Adipocyte differentiation has important implications for human diseases such as type II diabetes, hypertension and coronary heart disease. Ceramide and ceramide 1-phosphate, bioactive sphingolipids, are also implicated in diverse cellular processes such as differentiation, cell proliferation, apoptosis and inflammation.

  3. Antitumor Activity
    Myriocin, antifungal metabolite, inhibits B16F10 melanoma cell proliferation without cytotoxicity via G2/M arrest and reduces the levels of sphingolipid metabolites. The myriocin inhibition of cell proliferation in the melanoma cells may occur by blocking the sphingolipid biosynthesis pathway and depleting sphingosine, ceramide and ceramide 1-phosphate.

 

Selected Publications

  1. Yoo, H.S.; Hong J.T.; Lee, Y.M.; Yun, Y.P.; Lee, Y.S.; Choi, K.M.; Choi, M.H.; Ji, S.Y.; Yoo, J.M. Simultaneous HPLC Analysis of Ceramide and Dihydroceramide in Human Hairs. Arch. Pharm. Res. 2009, 32, 1795-1801.
  2. Yoo, H.S.; Shin, H.W.; Kim, D.; Lee, Y.S.; Lee, B.J.; Kim, J.S.; Jang, S.; Lim, H.; Lee, Y.; Oh, S. Alteration of sphingolipid metabolism and pSTAT3 expression by dietary cholesterol in the gallbladder of hamsters. Arch. Pharm. Res. 2009, 32, 1253-1262.
  3. Yoo, H.S.; Yun, Y.P.; Pyo, M.Y.; Hong J.T.; Im, J.H., Jin, Y.R.; Lee, J.J.; Yu, J.Y.; Han, X.H.; Im, S.H. Antiplatelet activity of β-carboline alkaloids from Perganum harmala: A possible mechanism through inhibiting PLCγ2 phosphorylation. Vascul. Pharmacol. 2009, 50, 147-152.
  4. Yoo, H.S.; Yoon, C.H.; Kim, M.J.; Park, M.T.; Byun, J.Y.; Lee, Y.M.; Hyun, J.W.; Lee, S.J. Activation of p38 Mitogen-Activated Protein Kinase Is Required for Death Receptor-Independent Caspase-8 Activation and Cell Death in Response to Sphingosine. Mol. Cancer Res. 2009, 7, 361-370.
  5. Yoo, H.S.; Lee, Y.M.; Yim, Y.H.; Jin, Y.X.; Shi, L.H.; So, H.Y.; Kihara, A.; Igarshi, Y. A sphingosine kinase activity assay using direct infusion electrospray ionization tandem mass spectrometry. Anal. Biochem. 2008, 380, 35-40.
  6. Yoo, H.S.; Lee, Y.M.; Oh, S.; Suh, S.H.; Jang, S. Changes in iNOS, GFAP and NR1 expression in various brain regions and elevation of sphingosine-1-phosphate in serum after immobilized stress. Neurochem. Res. 2008, 33, 842-851.
  7. Yoo, H.S.; Mitsutake, S.; Yokose, U.; Kato, M.; Matsuoka, I.; Yoo, J.M.; Kim, T.J.; Fujimoto, K.; Ando, Y.; Sugiura, M.; Kohama, T.; Igarashi, Y. The generation and behavioral analysis of ceramide kinase-null mice, indicating a function in cerebellar Purkinje cells. Biochem. Biophys. Res. Commun. 2007, 363, 519-524.
  8. Yoo, H.S.; Kim, T.J.; Jeon, J.; Jin, Y.R.; Son, D.J.; Hong J.T.; Ryu, C.K.; Shin, H.S.; Lee, K.H.; Yun, Y.P. Effects of KTJ740, a novel Antithrombotic agent, on platelet-derived growth factor-induced rat aortic smooth muscle cell proliferation and cell cycle progression. J. Cardiovasc. Pharmacol. 2007, 49, 280-286.
  9. Yoo, H.S.; Burenjargal, M.; Lee, Y.S.; Yoo, J.M.; Kim, Y.C.; Lee, Y.M.; Oh, S.; Yun, Y.P.; Hong J.T.; Chung, Y.B.; Moon, D.C. Endogenous sphingolipid metabolites related to the growth in Sphingomonas chungbukensis. Arch. Pharm. Res. 2007, 30, 317-322.
  10. Yoo, H.S.; Jang, S.; Lee, J.H.; Choi, K.R.; Kim, D.; Oh, S. Cytochemical alterations in the rat retina by LPS administration. Neurochem. Res. 2007, 32, 1-10.
  11. Yoo, H.S.; Lee, Y.M.; Kim, D.H.; Kie, J.H.; Jang, S.; Oh, S. Elevation of sphinganine 1-phosphate as a predictive biomarker for fumonisin exposure and toxicity in mice. J. Toxicol. Environ. Health Part A. 2006, 69, 2071-2082.
  12. Yoo, H.S.; Park, H.K.; Park, E.C.; Bae, S.W.; Park, M.Y.; Kim, S.W.; Tudev, M.; Ko, Y.H.; Choi, Y.H.; Kim, S.; Lee, B.B.; Yoon, J.B.; Park, J.E.; Kim, Y.W.; Kim, D.I. expression of heat shock protein 27 in human atherosclerotic plaques and increased plasma level of heat shock protein 27 in patients with acute coronary syndrome. Circulation. 2006, 114, 886-893.
  13. Yoo, H.S.; Kim, Y.J.; Suh, S.H.; Oh, S.; Park, H.S.; Lee, H.Y.; Ha, E.H. Reduced L-arginine level and decreased placental eNOS activity in preeclampsia. Placenta. 2006, 27, 438-444.
  14. Yoo, H.S.; Yun, Y.P.; Hong J.T.; Lee, Y.M.; Lee, Y.S.; Choi, H.K.; Oh, S.; Yoo, J.M. Protection of LLC-PK1 cells against hydrogen peroxide-induced cell death by modulation of ceramide level. Arch. Pharm. Res. 2005, 28, 311-318.
  15. Yoo, H.S.; Lee, Y.S.; Park, J.E.; Bae, S.W.; Stuhlinger, M.C.; Lee, S.H.; Choi, Y.H.; Pachinger, O.; Choi, B.Y.; Park, H.K.; Yu, K.H. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am. J. Cardiol. 2005, 95, 729-733.

Patents

  1. 알칼라인 포스파타아제의 탈인산화 후 오-프탈알데히드 유도체를 사용한 생체내 스핑고지질 1-인산과 스핑고지질의 동시정량 분석법 (특허등록:제0471943호)
  2. 신남알데히드 유도체 화학물을 함유하는 염증성 질환의 예방 및 치료용 약학조성물 (특허등록:제0676761호)
  3. 토마토로부터 리코펜을 직접 추출하는 방법(특허등록:제0692253호)
  4. 내부 표준물질을 이용한 생체시료내 세라마이드의 정량분석방법(특허등록:제0892988호)
  5. 파이토세라마이드를 포함하는 뇌혈관질환의 예방 및 치료용 의약 조성물 및 식품 조성물(특허출원:제20080079886호)
Yoon-Seok Roh
043-261-2819
ysroh@chungbuk.ac.kr

Education & Career

  • 2000-2008: DVM, College of Veterinary Medicine, Chonbuk National University
  • 2008-2011: PhD, Department of Pathology, College of Veterinary Medicine, Chonbuk National University (PI: Bumseok Kim)
  • 2012-2015: Postdoctoral Fellow (PI: Ekihiro Seki), Department of Pathology, University of California, San Diego, School of Medicine, CA, USA
  • 2015-2016: Postdoctoral Scientist (PI: Ekihiro Seki), Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
  • 2016-Present: Assistant Professor, College of Pharmacy, Chungbuk National University


Research Areas

  1. Target Discovery and Validation in Non-alcoholic Steatohepatitis (NASH)

  2. Identification of hepatocyte-derived secretome in transition from simple steatosis to NASH

  3. Mitochondrial Quality Control as a Therapeutic Target in Fatty Liver and metabolic syndrome

 

Selected Publications

I. Primary authorships (First author or Corresponding author):
P-1. Hepatology 2014 Jul;60(1):237-49. (IF: 14.079)
P-2. Journal of Clinical Investigation 2014 Aug;124(8):3566-78. (IF: 13.251)
P-3. Gastroenterology 2015 Jan;148(1):252-254. (IF: 20.773)
P-4. American Journal of Pathology 2018 Nov;188(11):2574-2588. (IF: 4.069)
P-5. Antioxidants & Redox Signaling 2019 May; Epub ahead of print (IF: 7.407)


II. Contributed authorships (co-author):
C-1. Nature Communications 2014 Jul 21;5:4451. (IF: 12.353)
C-2. Hepatology 2014 Feb;59(2):483-95. (IF: 14.079)
C-3. Gastroenterology 2013 May;144(5):1042-1054. (IF: 20.773)
C-4. Theranostics. 2018 Aug 7;8(16):4409-4428. (IF: 8.537)
C-5. Science Translational Medicine 2019 Jun; Epub ahead of print (IF: 16.71)